Pitavastatin eye injection for retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests a new eye injection containing pitavastatin, a drug normally used for cholesterol, wrapped in tiny particles. The goal is to see if it is safe and if it can help slow vision loss in people with retinitis pigmentosa.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have retinitis pigmentosa diagnosed by two eye doctors
- You are between 18 and 70 years old
- At least one eye has some remaining central vision (10 dB or higher on a visual field test)
- Your vision has been stable recently, with no big changes between tests
- The central part of your retina is not too thick (250 micrometers or less)
- You are willing to use birth control if you could become pregnant, or for men, use condoms for 3 days after each treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
This trial tests a gene therapy injection (UGX202) for people with advanced retinitis pigmentosa (RP) who have very poor vision. It aims to see if the treatment can help improve or preserve sight.
This trial tests an oral medication (NPI-001) to see if it can preserve the light-sensing cells in the retina for people with retinitis pigmentosa caused by Usher syndrome. It lasts 24 months and requires several eye exams to monitor changes.
This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.
This trial tests a new gene therapy injection (ZM-02) that uses light-sensitive proteins to help restore vision in people with advanced retinitis pigmentosa. It’s designed to see if the treatment is safe and can improve vision.
This trial tests a drug called NPI-001 (N-acetylcysteine) to see if it can help protect the light-sensing cells in the eyes of people with Usher syndrome, a genetic condition that causes vision and hearing loss. The study lasts 24 months and measures how well the retina stays healthy.
Hear when a new Retinitis Pigmentosa (RP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.